AI assistant
CRISPR Therapeutics AG — Director's Dealing 2021
Mar 12, 2021
30936_dirs_2021-03-12_d1817f25-5590-4c8e-8b17-6a295f2a3d75.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2021-03-10
Reporting Person: Klein Lawrence Otto (CBO & COO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-10 | Common Shares | M | 4583 | — | Acquired | 15191 | Direct |
| 2021-03-10 | Common Shares | F | 2141 | $124.15 | Disposed | 13050 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-11 | Stock Option (Right to Buy) | $133.88 | A | 33334 | Acquired | 2031-03-11 | Common Shares (33334) | Direct |
| 2021-03-11 | Restricted Stock Units | $ | A | 12000 | Acquired | Common Shares (12000) | Direct |
Footnotes
F1: This restricted stock unit award was granted on March 10, 2020 with respect to 13,750 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.
F2: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F4: This option was granted on March 11, 2021 with respect to 33,334 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 11, 2021.
F5: This restricted stock unit award was granted on March 11, 2021 with respect to 12,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024 and (iv) one quarter of the shares vesting on March 11, 2025.